These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 35721432)

  • 1. Rates, types, and associated factors of acute adverse effects after the first dose of ChAdOx1 nCoV-19 vaccine administration in Thailand.
    Watcharananan SA; Nadee C; Kongsuwattanaleart P; Sangthong N; Ngorsakun P; Vimonvattaravetee P; Phuphuakrat A; Udomsubpayakul U
    IJID Reg; 2022 Mar; 2():35-39. PubMed ID: 35721432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
    Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
    J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events following introduction of the ChAdOx1 nCoV-19 vaccine in Somalia in 2021: findings from a fragile setting and implications for the future.
    Hamayoun M; Abdulrazak I; Farid M; Malik MR; Mohamud MF
    IJID Reg; 2022 Sep; 4():47-52. PubMed ID: 35720961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination.
    Sheng WH; Chang SY; Lin PH; Hsieh MJ; Chang HH; Cheng CY; Yang HC; Pan CF; Ieong SM; Chao TL; Chen JP; Cheng SH; Chang SC
    J Formos Med Assoc; 2022 Apr; 121(4):766-777. PubMed ID: 35305895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
    Lazarus R; Baos S; Cappel-Porter H; Carson-Stevens A; Clout M; Culliford L; Emmett SR; Garstang J; Gbadamoshi L; Hallis B; Harris RA; Hutton D; Jacobsen N; Joyce K; Kaminski R; Libri V; Middleditch A; McCullagh L; Moran E; Phillipson A; Price E; Ryan J; Thirard R; Todd R; Snape MD; Tucker D; Williams RL; Nguyen-Van-Tam JS; Finn A; Rogers CA;
    Lancet; 2021 Dec; 398(10318):2277-2287. PubMed ID: 34774197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factors for Grade 3 to Grade 4 Adverse Reactions to the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2.
    Lee SW; Lee H; Lee SK; Moon JY; Moon S; Chung SJ; Yeo Y; Park TS; Won Park D; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Med (Lausanne); 2021; 8():738049. PubMed ID: 34660644
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase 2/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India.
    Kulkarni PS; Padmapriyadarsini C; Vekemans J; Bavdekar A; Gupta M; Kulkarni P; Garg BS; Gogtay NJ; Tambe M; Lalwani S; Singh K; Munshi R; Meshram S; Selvavinayagam TS; Pandey K; Bhimarasetty DM; Ramakrishnan SR; Bhamare C; Dharmadhikari A; Vadakkedath R; Bonhomme CJ; Thakar M; Kurle SN; Kelly EJ; Gautam M; Gupta N; Panda S; Bhargava B; Shaligram U; Kapse D; Gunale B;
    EClinicalMedicine; 2021 Dec; 42():101218. PubMed ID: 34870133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
    Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
    Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea.
    Jeon M; Kim J; Oh CE; Lee JY
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age.
    Tanner R; Starr N; Chan G; Dempsey E; Heffernan E; Newman E; O'Neill J; Hannan MM; Lynch B; Joyce E
    J Heart Lung Transplant; 2022 Apr; 41(4):492-500. PubMed ID: 35090809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021.
    Konu YR; Gbeasor-Komlanvi FA; Yerima M; Sadio AJ; Tchankoni MK; Zida-Compaore WIC; Nayo-Apetsianyi J; Afanvi KA; Agoro S; Salou M; Landoh DE; Nyansa AB; Boko E; Mijiyawa M; Ekouevi DK
    Arch Public Health; 2021 Nov; 79(1):207. PubMed ID: 34819146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines.
    Kim JY; Bae S; Park S; Kwon JS; Lim SY; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Heo J; Shum D; Jee Y; Kim SH
    Immune Netw; 2021 Aug; 21(4):e29. PubMed ID: 34522442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey.
    Cherian S; Paul A; Ahmed S; Alias B; Manoj M; Santhosh AK; Varghese DR; Krishnan N; Shenoy P
    Rheumatol Int; 2021 Aug; 41(8):1441-1445. PubMed ID: 34142203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period.
    Kim JY; Lim SY; Park S; Kwon JS; Bae S; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Kim K; Shum D; Jee Y; Kim SH
    J Infect Dis; 2022 Mar; 225(5):777-784. PubMed ID: 34850034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of acute demyelinating polyradiculoneuropathy with bilateral facial palsy after ChAdOx1 nCoV-19 vaccine.
    Nasuelli NA; De Marchi F; Cecchin M; De Paoli I; Onorato S; Pettinaroli R; Savoini G; Godi L
    Neurol Sci; 2021 Nov; 42(11):4747-4749. PubMed ID: 34272622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
    Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
    J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.